However, our study demonstrated that Bt spore-crystals genetically modified to express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A induced hematotoxicity, particularly to the erythroid lineage.
This finding corroborates literature that demonstrated that alkali-solubilized Bt spore-crystals caused in vitro hemolysis in cell lines of rat, mouse, sheep, horse, and human erythrocytes and suggested that the plasma membrane of susceptible cells (erythrocytes, in this case) may be the primary target for these toxins  The study also found:
- That Cry toxins are capable of exerting their adverse effects when suspended in distilled water, not requiring alkalinization via insect physiology to become activated as formerly believed.
- That a dose of Cry1Ab as low as 27 mg/kg, their lowest tested dose, was capable of inducing hypochromic anemia in mice – the very toxin has been detected in blood of non-pregnant women, pregnant women and their fetuses in Canada, supposedly exposed through diet.
- Whereas past reports have found that Bt toxins are generally nontoxic and do not bioaccumulate in fatty tissue or persist in the environment, the new study demonstrated that all Cry toxins tested had a more pronounced effect from 72 hours of exposure onwards, indicating the opposite is true.
- That high-dose Cry toxin doses caused blood changes indicative of bone marrow damage (damage to “hematopoietic stem cell or bone marrow stroma”).
The authors noted their results “demonstrate leukemogenic activity for other spore-crystals not yet reported in the literature.” They concluded:
[R]esults showed that the Bt spore-crystals genetically modified to express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A can cause some hematological risks to vertebrates,increasing their toxic effects with long-term exposure. Taking into account the increased risk of human and animal exposures to significant levels of these toxins, especially through diet, our results suggest that further studies are required to clarify the mechanism involved in the hematotoxicity found in mice, and to establish the toxicological risks to non-target organisms, especially mammals, before concluding that these microbiological control agents are safe for mammals.
Their conclusion is that it is premature to consider GM toxins to be safe in mammals. Billions have already been exposed to Bt toxins, in combination with glyphosate-based herbicide formulations such as Roundup, and yet, most biotech research scientists and industry regulators still claim they are unequivocally safe. This has much to do with the well-known relationship that biotech corporations like Monsanto have with so-called ‘check book’ science firms who are basically paid to obfuscate adverse health outcomes of their products, such as the GMO-Cancer link. [see: Monsanto-Funded Science Denies Emerging Roundup Cancer Link http://www.greenmedinfo.com/blog/monsanto-funded-science-denies-emerging-roundup-cancer-link. The newest study, published in the journal Regulatory Toxicology and Pharmacology titled, “Epidemiologic studies on glyphosate and cancer: A review,” declared its glaring conflict of interest in the following manner:
“ Conflict of Interest Statement
The authors have disclosed the funding source for this research. JSM [study author] has served has a paid consultant to Monsanto Company. Final decisions regarding the content of the manuscript were made solely by the four authors.
This research was supported by the Monsanto Company, St. Louis, Missouri
Study Finds that GMO Insulin Causes Type 1 Diabetes in Type 2 Diabetics
A new study published in the Journal of Clinical Endocrinology &Metabolism by Nishida et al in 2014 titled, “Insulin administration may trigger type 1 diabetes in Japanese type 2 diabetes patients with type 1 diabetes high-risk HLA class II and the insulin gene VNTR genotype,” is shedding light on a possible explanation for why insulin treatment may accelerate morbidity and mortality in type 2 diabetics. The study revealed that giving genetically susceptible type 2 diabetes patients recombinant insulin can trigger their bodies to target their own insulin producing cells for autoimmune destruction, effectively producing ‘double diabetes’: type 1 and type 2, as a result. The Japanese study took 6 patients (4 men and 2 women) with type 2 diabetes, none of whom had previously received insulin therapy nor had markers for autoantibodies to their own insulin (e.g. GAD65). All patients were found to have the type 1 diabetes susceptibility gene known as type 1 diabetes high risk HLA class II (IDDM1), which is considered to play a role in up to 50% of type 1 diabetes cases, and the insulin gene VNTR genotype (IDDM2), believed to play a key role in susceptibility to type 2 diabetes.
After recombinant insulin administration their blood glucose control deteriorated, and their own insulin producing beta cells – as measured by declining C-peptide levels (a marker for the production of natural insulin) – decreased insulin production to a deficiency levels commonly found in type 1 diabetes patients. The average time it took for the patients to develop full blown type 1 diabetes was 7.7 months, with one patient developing the condition within 1.1 months. Further tests revealed that the patients had antibodies against their own pancreatic islet cells (the cells responsible for producing insulin), insulin allergy or increased levels of insulin antibody. Additionally, 2 of 4 cases were found to have GAD-reactive and insulin peptide reactive Th1 cells, typical markers of autoimmunity induced type 1 diabetes. The researchers concluded from their findings:
“The findings suggest that insulin administration may have triggered TIDM in patients with T2DM. IDDM1 and IDDM 2 as well as autoreactive T cells may contribute to the development of T1DM. Developing insulin-triggered T1DM if a patient’s blood glucose control acutely deteriorates after insulin administration should be carefully considered.”
The researchers also pointed out that there are a number trials underway to produce vaccines containing insulin intended to induce a ‘tolerogenic immune response’ and therefore ameliorate autoimmune type 1 diabetes. http://www.greenmedinfo.com/blog/gmo-insulin-causes-type-1-diabetes-type-2-diabetics
Clearly, however, their findings run contrary to this expectation, revealing that it is possible that introducing exogenous forms of insulin may stimulate the opposite reaction and induced autoimmunity against the hormone, or the cells in the pancreas responsible for producing it.
Discussion: GMO Insulin Not the Same As Animal Derived Insulin
A possible explanation for these results lies in the difference between today’s synthetic insulin and insulin purified from animals such as pigs (porcine insulin), which is no longer available in countries like the U.S. Insulin was actually the first protein to be synthesized with recombinant DNA (GMO) technology in the late 1970s, http://www.greenmedinfo.com/blog/gmo-insulin-causes-type-1-diabetes-type-2-diabetics-study-finds and today, products like Lantus (insulin glargine [rDNA origin] injection) dominate the market. According to Sanofi, Lantus’ manufacturer their form is produced “by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.
” Synthetic insulin is classified as an insulin analog that differs significantly from human insulin in its primary amino acid structure: “Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.” Lantus’ formulation also contains various ‘inactive ingredients,’ such as:
- hydrochloric acid • sodium hydroxide (lye)
- m-cresol (a coal tar derivative)
- polysorbate 20
The simultaneous injection of these antigenic ingredients along with synthetic insulin could be responsible for hypersensitizing the immune system against insulin in the same way that inactive and adjuvant ingredients in vaccines induce exaggerated immune reactions against the ‘active’ vaccine antigen (e.g. the viral or bacterial antigen) which sometimes results in the immune system attacking self-structures (autoimmunity). Furthermore, synthetic insulin does not have the same conformational state – i.e. it does not assume the same complex folded form – of natural human insulin, or more closely related pig insulin. This presents a ‘recognition’ problem from the perspective of the immune system which may identify the foreign protein as ‘other’ generating acute or sustained autoimmune reactions to it as a result.
According to a 1993 paper on recombinant human insulin , “Bacterially expressed proteins normally lack any secondary structure or post-translational modifications” – a highly significant fact, considering that complex proteins such as hormones actually have four levels of folding complexity: primary, secondary, tertiary and quaternary, all of which together determine the protein’s natural structure and therefore its function. In fact, this complexity is so immense that Levinthal’s paradox states a fully folded protein (i.e., one that has attained its native conformation) must pass through such a large number of degrees of freedom to reach its native state that there is not enough time in the universe for it to move through all possible configurations to the one it was designed by nature to assume. Obviously, if synthetic insulin is not capable of obtaining the same 3-dimensional structure as natural insulin, nor is modified post-translationally through epigenetic regulatory processes, it cannot behave in the same way as natural insulin in the body, and would likely be identified as ‘other’ by the immune system, if not also cellular insulin receptors.
Research dating back to the early 1980s compared synthetic E. Coli derived insulin with porcine (pig) derived insulin in diabetic children and found that porcine insulin was more effective at lowering HbA1 values (a marker of damage associated with elevated blood sugar), superior at reducing fasting glucose concentrations, and less antibody reactive to insulin than synthetic insulin. While pig derived insulin has its limitations, especially considering there are limits to how much can be produced, clearly it is more appropriate than synthetic versions if it is true that the latter is incapable of reproducing the same therapeutic outcome for diabetics.
Natural Approaches To Diabetes Prevention and Treatment are the Future
The future of medicine will look to identifying and removing the causes of conditions like diabetes, instead of employing patented synthetic drugs and synthetic replacement therapies (which feed the deficiency), palliatively — especially considering the new research indicating they actually make the patient far worse. Also, diet is the #1 factor in the pathogenesis of most chronic conditions that afflict the modern world; more specifically, the consumption of foods or food-like products that deviate from our ancestral diets generate the physiological conditions that produce disease in the first place. Addressing the dietary causes and incompatibilities and many ‘diseases’ decelerate and may even regress.
New Study Links GMOs to Gluten Disorders That Affect 18 Million Americans
This study was recently released by the Institute for Responsible Technology (IRT), and uses data from the US department of Agriculture, US Environmental Protection Agency, medical journal reviews as well as other independent research. The authors relate GM foods to five conditions that may either trigger or exacerbate gluten-related disorders, including the autoimmune disorder, Celiac Disease:
- Intestinal permeability
- Imbalanced gut bacteria
- Immune activation and allergic response
- Impaired digestion
- Damage to the intestinal wall
The Institute for Responsible technology is a world leader in educating policy makers and the public about GMO foods and crops. The institute reports and investigates on the impact GM foods can have on health, environment, agriculture and more. The full 24-page report, a press release, a recorded interview and a summary of the research can be found here. http://www.greenmedinfo.com/blog/news-release-gmos-linked-exploding-gluten-sensitivity-epidemic-free-pdf1
Study Links Genetically Modified Corn to Rat Tumors
In November 2012, The Journal of Food and Chemical Toxicology published a paper titled ‘Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize’ by Gilles-Eric Seralini and his team of researchers at France’s Caen University. It was a very significant study, which obviously looks bad for the big bio tech companies like Monsanto, being the first and only long term study under controlled conditions examining the possible effects of a diet of GMO maize treated with Monsanto roundup herbicide. This study has since been retracted, which is odd, because the journal it was published in is a very well known, reputable peer reviewed scientific journal. In order for a study to be published here it has to go through a rigorous review process. It’s also important to note that hundreds of scientists from around the world have condemned the retraction of the study. This study was done by experts, and a correlation between GMOs and these tumors can’t be denied, something happened. Here you can see image of tumors induced through the experiment. http://www.greenmedinfo.com/blog/alert-gmo-corn-and-roundup-caused-cancer-and-killed-rats?page=1
The multiple criticisms of the study have also been answered by the team of researchers that conducted the study. You can read them and find out more about the study here. https://www.gmoseralini.org/category/critics-answered/